To examine the association between access restrictions on celecoxib use and healthcare costs in Medicare patients with arthritis. METHODS: Enrollees diagnosed with osteoarthritis (OA) or rheumatoid arthritis (RA) between January 1, 2008 and December 31, 2010 (index date) and at least 24 months of continuous health plan enrollment (I-year pre-and post-index date) were identified from 12 health plans with and without access restrictions to celecoxib in the MarketScan ® Medicare Supplemental and Coordination of Benefits Database. Utilization of celecoxib, all-cause, gastrointestinal (GI) event-related, and OA/RA-related healthcare utilization and expenditures over a 12-month follow-up period were compared for enrollees in restricted and unrestricted plans. RESULTS: The restricted group (Nϭ27,595) was similar to the unrestricted group (Nϭ57,890) at baseline in terms of the prevalence of OA/RA, serious GI events, and Charlson Comorbidity Index (CCI) score; however, celecoxib use was significantly lower in the restricted group (11.8% vs. 13.5%, pϽ0.001). Total baseline medical costs were significantly higher for the restricted group as compared to the unrestricted group ($13,641 vs. $10,456, pϽ0.001), whereas pharmacy costs were lower ($3,873 vs. $4,488, pϽ0.001) for the restricted group. No differences were observed between the two groups in GI eventrelated costs ($643 vs. $602, pϭ0.127). Total OA/RA related costs were significantly higher in the restricted group than the unrestricted group ($9,432 vs. $6,642, pϽ0.001), which were primarily driven by inpatient costs ($6,215 vs. $3,857, pϽ0.001). All-cause total costs were also significantly higher in the restricted group than in the unrestricted group ($25,428 vs. $20,793, pϽ0.001), which were primarily driven by the costs of inpatient and outpatient services. CONCLUSIONS: Enrollees in plans with access restrictions to celecoxib had lower utilization of celecoxib. No differences were observed between the groups in GI event-related costs. All-cause and OA/RA-related costs, howver, were significantly higher among enrollees in plans with access restrictions. 
PMS68 CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH TERIPARATIDE ADHERENCE IN MEDICARE PART D RECIPIENTS: A RETROSPECTIVE COHORT STUDY

OBJECTIVES:
To evaluate the utilization patterns of Medicare Part D beneficiaries newly started on teriparatide and the association of adherence with fracture outcomes and health care utilization. METHODS: A retrospective cohort analysis was performed using medical and pharmacy claims of 761 Humana members aged 18 and older with first prescription fills for teriparatide between January 2008 and December 2009. Low Income Subsidy enrollees were excluded. Descriptive analyses summarized baseline characteristics, healthcare use, and costs at 12 and 24 months post teriparatide initiation. Adherence was measured by Proportion of Days Covered (PDC), categorized as high (PDC Ն80%), intermediate (50% ϽPDC Ͻ80%Ͼ), and low (PDC Յ50%). Multivariate logistic regression was used to evaluate associations of adherence with fracture rates. RESULTS: Six months before teriparatide initiation, 50.7% of the cohort (386 patients) had at least 1 fracture episode, although there was low overall comorbidity (Deyo Charlson mean 1.1). At 12 months, 21% of the cohort was highly adherent, whereas at 24 months, only 13% was highly adherent (272 patients). More low adherent patients visited the ER or had inpatient visits at 12 months than highly adherent patients (33% vs. 24%; pϽ0.05; 21% vs. 16%; NS). Total health care costs were greater at 12 months in highly-adherent patients ($21,033 vs. $15,528; p Ͻ0.05) . Among the highly adherent, 64% of costs was pharmacy-related. At 12 months, only 18% of the 222 patients with fractures was highly adherent; this group had the highest overall fracture-related costs, of which 89% was pharmacy-related. The regression models demonstrated no significant association between teriparatide adherence and 12-month fracture outcomes (ORϭ0.81, 95% C.I. 0.53 -1.24). CONCLUSIONS: Similar to previous studies of patients with osteoporosis, adherence to prescribed therapy was suboptimal. Highly-adherent patients appeared to have higher overall costs due to higher pharmacy costs, whereas patients with low adherence had higher health care utilization. 
PMS69 TUMOR NECROSIS FACTOR BLOCKER DOSE ESCALATION AMONG BIOLOGIC NAÏVE RHEUMATOID ARTHRITIS (RA) PATIENTS IN COMMERCIAL MANAGED CARE PLANS IN THE TWO YEARS FOLLOWING THERAPY INITIATION
OBJECTIVES:
To estimate national and regional dose escalation patterns over two years of therapy among biologic naïve RA patients initiating etanercept, adalimumab, or infliximab using US managed care data. METHODS: Adult (ages 18-65) RA patients who did not use RA biologics in the prior six months, initiating etanercept, adalimumab, or infliximab between July 1, 2005 and April 30, 2009 were identified using the MarketScan® Commercial Database. National and regional dose escalation rates were evaluated 12 and 24 months after initiation using the Single Instance Method (one claim with an average weekly dose at least 115%, 130%, or 150% greater than the initial weekly dose) and the Two Instances Method (two consecutive claims with an average weekly dose 130% greater than the initial weekly dose). Dose escalation rates were compared using Fisher's Exact tests. RESULTS: A total of 2,747 patients met the inclusion criteria (mean age 50 years (SDϭ10), 74% female). More patients resided in the South (45%) than North Central (28%), West (17%) or East (10%) US regions. More patients (44%) initiated etanercept than adalimumab (37%) or infliximab (20%). In the first year of therapy, dose escalation ranged from 0.8%-1.5% for etanercept, 10.8%-12.5% for adalimumab, and 16.4%-42.5% for infliximab using the single instance method; ranges at 24 months were 0.8%-2.1% for etanercept, 14.3%-17.5% for adalimumab, and 26.4%-57.6% for infliximab. At 12 and 24 and months respectively, the two instances method showed lower dose escalation rates for etanercept (0.8%, 0.8%) than adalimumab (8.7%, 13.3%) or infliximab (22.9%, 37.6%) at the 130% threshold (pϽ0.001). Dose escalation rates were consistent across US geographic regions, with etanercept having less dose escalation than adalimumab or infliximab across all regions. CONCLUSIONS: RA patients initiating etanercept had lower dose escalation rates than patients initiating adalimumab or infliximab in the first and second year following therapy initiation and across US geographic regions. 
PMS70 TUMOR NECROSIS FACTOR (TNF)-BLOCKER DOSE ESCALATION AMONG PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN A LARGE MANAGED CARE POPULATION IN THE UNITED STATES
OBJECTIVES:
To estimate dose escalation rates of etanercept, adalimumab, and infliximab for RA patients initiating and continuing TNF-blockers METHODS: This retrospective analysis in the HealthCore Integrated Research Database identified adult (18-64 years) RA patients with Ն1 claim for etanercept, adalimumab, or infliximab between July 1, 2007 and January 31, 2010 (first claimϭindex). Patients were continuously enrolled for 6 months prior to index; patients with TNF-blocker claims within 6 months prior to index were considered continuing therapy. Patients with other indicated conditions or contraindicated to RA biologic therapy were excluded. Dose escalation, assessed over a 12-month period of continuous treatment (Ͻ60-day gap), was defined as: 1) 2ϩ instances in which subsequent doses were Ն130% of index dose or 2) any instances with increased number of syringe/vial or shortened dosing interval. RESULTS: Overall, 3868 patients were included (mean age 50.1 years; 74.4% female). Among new patients (932 etanercept; 267 adalimumab; 292 infliximab), 4.4%, 9.0%, and 42.5% of etanercept, adalimumab, and infliximab patients, respectively, had 2ϩ instances of dose escalation (pϽ0.001 for all 2-way comparisons). Most new patients (85.3% etanercept; 92.1% adalimumab; N/A infliximab) initiated therapy at recommended dose; of these patients, 2.3%, 12.6%, and 59.9% of etanercept, adalimumab, and infliximab patients, respectively, increased by Ն1 syringe/vial or shortened dosing frequency. Among continuing patients (1078 etanercept; 480 adalimumab; 819 infliximab), 6.0%, 16.9%, and 29.1% of etanercept, adalimumab, and infliximab patients, respectively, had 2ϩ instances of dose escalation (pϽ0.0001 for all 2-way comparisons). Most continuing patients (93.5% etanercept; 95.6% adalimumab; N/A infliximab) received the index dose at recommended dose; of these, 4.1%, 19.6%, and 79.5% of etanercept, adalimumab, and infliximab patients, respectively, increased by Ն1 syringe/ vial or shortened dosing frequency. CONCLUSIONS: Etanercept had lower dose escalation rates for new and continuing patients compared with adalimumab and infliximab in a large US managed care plan. 
PMS71 COST-EFFECTIVENESS OF ALENDRONATE THERAPY FOR OSTEOPENIC POSTMENOPAUSAL WOMEN IN JAPAN
OBJECTIVES:
The purpose of this study was to estimate the cost-effectiveness of alendronate therapy for osteopenic postmenopausal women in Japan. METHODS: A Markov model with six health states (no fracture, post-vertebral fracture, posthip fracture, post-vertebral and hip fracture, bedridden, and death) was developed to predict lifetime costs and quality-adjusted life years (QALYs) of five years of alendronate therapy versus no drug treatment in postmenopausal women without fracture history. Fracture risk associated with age and bone mineral density (BMD) was derived from epidemiologic studies in Japan. We ran the model with different combinations of age (65 to 75), BMD (70% -80% of the young adult mean (YAM)), and the number of clinical risk factors (CRFs, one to three). Probabilistic sensitivity analysis was performed to assess parameter uncertainty. RESULTS: The model was sensitive to age, BMD, and CRFs. The incremental cost-effectiveness ratio (ICER) was below $50,000 per QALY in the following scenarios: 1) In 70-year-old women with BMD 70% of YAM, who had two CRFs, 2) In 75-year-old women with BMD 70% of YAM, who had two CRFs. In 65-year-old women with BMD 70% of YAM, who had three CRFs, 3) In 70-year-old women with BMD 70% and 75% of YAM, who had three CRFs, and 4) In 75-year-old women with BMD 70% and 75% of YAM, who had three CRFs. Applying a willingness to pay threshold of $50,000 per QALY, the probability of being cost-effective was estimated to 2.9 %, 36.5%, and 99.2% in 70-year-old women with BMD 70% of YAM with one CRF, two CRFs, and three CRFs, respectively. CONCLUSIONS: Whether to treat osteopenic postmenopausal Japa-
nese women should be determined with consideration for multiple CRFs in terms of cost-effectiveness. 
PMS72 EVALUATION OF CLINICAL PERFORMANCE AND VARIATION AMONG THREE TYPES OF PATIENTS WITH RHEUMATOID ARTHRITIS: OPPORTUNITIES TO RAISE QUALITY AND LOWER COSTS
OBJECTIVES:
To determine the quality and variability of care in rheumatoid arthritis (RA). METHODS: We recruited 109 board-certified rheumatologists. Physicians evaluated 3 common RA cases: A) mild disease activity, inadequately treated with conventional disease modifying antirheumatic drugs (DMARDs); B) increasing disease activity, inadequately treated with conventional DMARDs; and C) stable disease activity, adequately treated with DMARDs, with a complicating co-morbidity. Clinical performance and value (CPV) vignettes, a validated case-mix adjusted measure of clinical practice, assessed variability and quality of care. Consented physicians completed one online vignette for each case-type obtaining a history, physical examination, ordering tests and determining treatments. Criteria for evaluating clinical decisions were based on ACR guidelines, published evidence and expert panels. Vignette scores are reported as percentages of total criteria correct overall and by domain, (e.g., treatment prescribed). RESULTS: The mean quality score for all simulated cases (nϭ327 cases) was 61.3%%. Mean scores for history were 62.8%; physical examination: 55.8%; laboratory testing and imaging: 61.1%; disease activity assessment: 52.6% and treatment: 66.9%. Ordering unnecessary tests was most common: rheumatologists ordered 1.8 additional laboratory and 1 additional imaging test. Among the 3 case types, lowest quality and most clinical variability occurred in the case with the co-morbidity (Case C), associated with unnecessary testing and inappropriate use of biologic and/or combination DMARDs. Variability was also found in Cases A and B: 3 of 10 and 2 of 10 rheumatologists, respectively, used combination and/or biologic DMARDs unnecessarily. CONCLUSIONS: Improving quality and lowering cost is a strategic focus of payers and providers. Using CPV vignettes, we found a wide range of variation in RA practice, which resulted in unnecessary testing, repetition of potentially expensive imaging studies and varying use of DMARDs. This variability indicates there are opportunities to improve quality of care and lower costs. 
PMS73 A SYSTEMATIC LITERATURE REVIEW OF ECONOMIC STUDIES AND A COST ANALYSIS RELATED TO EPIDURAL STEROID INJECTIONS IN THE ELDERLY
OBJECTIVES:
To appraise existing economic evaluations of epidural steroid injections (ESIs) for lumbar spinal stenosis and to estimate Medicare-based reimbursed amounts. METHODS: We searched PubMed through June 2011 for low back pain, spinal stenosis or sciatica, and ESI and included observational studies with cost outcomes. We performed a supplementary descriptive analysis of Medicare reimbursed amounts associated with ESI performed at a single institution in 2010. RESULTS: Our literature search indicated that rates of lumbar ESI increased 271% from 1994 to 2001 in Medicare beneficiaries Ն65 years of age with professional charges per injection nearly doubling ($115 to $227) during this time period. A second study found the rate of lumbar epidurals was 67% higher in 2006 versus 2002 in Medicare beneficiaries of any age, and allowed charges of all spine epidural increased from $336 to $395. Our single-institution estimation sample included 279 patients receiving one (nϭ179), two (Nϭ93), three (Nϭ30), or four (Nϭ2) ESIs. We estimated mean total Medicare reimbursement per outpatient ESI episode procedure to be $635 in 2010 (technical reimbursement and estimated professional payment). The associated reimbursement estimates were $1239 and $1834 for those receiving 2 and 3 ESI episodes, respectively. CONCLUSIONS: There are few studies investigating the economic impact of ESI procedures for lumbar spinal stenosis in the elderly, or providing estimates of technical and professional reimbursement amounts. Our single-institution estimate suggests that Medicare-based reimbursement is greater than $600 per ESI (technical and professional). More information on utilization, costs, and cost-effectiveness of ESI in treating lumbar spinal stenosis are needed.
PMS74 DEVELOPING AND IMPLEMENTING PATIENT-RESOURCE USE DIARIES FOR A CLINICAL TRIAL ASSESSING SPINAL STENOSIS INTERVENTIONS IN THE ELDERLY
Bresnahan BW, Rundell S, Comstock B, Sullivan SD, Jarvik JG, Nguyen H, Bauer Z, Friedly J University of Washington, Seattle, WA, USA OBJECTIVES: To develop and implement patient-reported resource use questionnaires for assessing utilization and costs in elderly patients with lumbar spinal stenosis (SS), as part of an epidural steroid injection randomized clinical trial (RCT) in multiple integrated health systems. METHODS: We developed patient-completed diaries for a RCT in an elderly population with SS to capture medication use, time, and costs incurred by patients. Diary sections included: prescription opioid medications, non-opioid analgesics and over-the-counter (OTC) products, therapeutic services, time spent for SS care, and products purchased for back pain. We summarized demographics and commonly-reported opioid medications for currently-enrolled subjects. RESULTS: We implemented resource use diaries in a RCT during baseline to week 3, weeks 4-6, weeks 24-26, and weeks 50-52. Overall, the diaries capture 12 weeks of data, distributed at key time points, during 12 months.
The prescription opioid section and OTC section collect dose and daily medication use intensity. Later sections capture weekly visits, time, and purchases for back pain. We integrated the patient questionnaires into our overall electronic data management system, including prompts for sites to send participants diaries, collect diaries and enter the data on our RedCap™ electronic data capture system. To date, 100 RCT participants completed baseline diaries. The mean age was 69.6 years, 59% were females, and approximately 29% were from minority groups. The most commonly reported opioid medications were hydrocodone-acetaminophen and acetaminophen-codeine. CONCLUSIONS: It is important to capture the patient perspective in RCTs, particularly those with complex interactions among pain, functioning, medication use and economic endpoints. Electronic medical records are powerful tools to assess clinical and economic resource use, but still have limitations on collecting what patients spend and do to manage their pain condition. Logistical challenges and patient burden of completing questionnaires must be weighed against a more comprehensive economic evaluation and management of a high-priority condition. 
PMS75 ANNUAL GOLIMUMAB UTILIZATION AND COSTS FOR PSORIATIC ARTHRITIS PATIENTS ENROLLED IN MANAGED CARE PLANS
OBJECTIVES:
To calculate expected mean annual golimumab costs based on observed one-year dosing patterns within a managed care population of psoriatic arthritis (PsA) patients. METHODS: IMS LifeLink™ Health Plan Claims database was utilized to identify patients with: index golimumab claim (4/24/2009-01/06/2010); age Ն18 years at index; Ն1 PsA diagnosis code (696.0); and 12/Ն 12 months pre-/ post-index continuous enrollment. Biologic experience was defined as Ն1 medical/ pharmacy claims for another biologic 12 months prior to the first golimumab prescription. Golimumab utilization was reported as the proportion of patients and prescriptions at the recommended 50 mg dose, and prescription intervals, for the 12 month post-index period. Annual costs were modeled using the golimumab United States wholesale acquisition cost (effective 7/5/2011) of $1,941.65 per 50 mg. RESULTS: 127 PsA patients receiving golimumab (nϭ914 prescriptions) were identified; 59.8% were female; meanϮSD age was 49Ϯ10 years. The majority (78.7%) of patients had pre-index biologic experience; 73.0% experienced 1 unique biologic, 24.0% experienced 2 unique biologics, and 3.0% experienced 3ϩ unique biologics at some time point before golimumab. A 50 mg golimumab dose was dispensed in 95.3% of all PsA patients upon initiation and 96.6% of all prescriptions. The dose at each of the first 12 prescription fills was 50 mg for 95.2%-97.9% of patients. A 50 mg dose was dispensed upon initiation in 94.0% and 100.0% of biologic-experienced and non-biologic-experienced PsA patients, respectively. Overall meanϮSD interval between prescriptions was 32Ϯ14 days; median was 30 days. Based upon observed prescription intervals, a mean annual acquisition cost of $22,135 would be realized. CONCLUSIONS: The majority of PsA patients receiving golimumab was biologic-experienced and received a 50 mg dose on a monthly basis with no apparent increased dose requirement. Estimated average annual per patient golimumab cost in a managed care PsA population would be $22,135. 
PMS76 TWO-YEAR DIRECT HEALTH CARE COST BURDEN OF PSORIATIC ARTHRITIS TO MANAGED CARE: A RETROSPECTIVE CASE STUDY OF GOLIMUMAB PATIENTS
OBJECTIVES:
To describe the 2-year disease-related direct healthcare costs of psoriatic arthritis (PsA) patients, in managed care, prior to initiating golimumab (baseline). METHODS: The IMS LifeLink™ Health Plan Claims database was utilized to identify patients who had/were: index golimumab pharmacy claim started April 24, 2009-June 30, 2010; aged Ն18 years at index; Ն1 PsA ICD-9 diagnosis code (696.0); and 24 months pre-and Ն 6 months post-index continuous enrollment. Total disease-related direct healthcare costs included medical (inpatient, outpatient) and pharmacy (biologic and non-biologic treatment) costs. Disease-related allowable healthcare costs were calculated from outpatient and inpatient claims with an ICD-9 diagnosis code for PsA (696.0) or rheumatoid arthritis (RA-714.xx). Pharmacy costs were calculated from allowed costs for biologic and non-biologic treatments used in PsA, RA, or psoriasis. RESULTS: A total of 211 golimumab patients with PsA (nϭ180 with pre-index biologic experience) were analyzed; meanϮSD age was 50Ϯ10; 61.1% female. Concomitant diagnosis codes for RA or psoriasis were found in 39.8% and 51.2% of all PsA patients, respectively. Total meanϮSD pre-index PsA-related costs were $3,569Ϯ$9,231. Mean PsA-related outpatient medical costs represented 92.0% of total PsA-related costs. Among the 114 patients with a comorbid RA diagnosis code, overall mean pre-index total RA-related costs were $2186. Mean disease-related pharmacy costs for the 2-year period prior to golimumab totaled $28,041. Based on the disease-related outpatient, inpatient, and pharmacy costs, the 2-year direct mean per patient disease-related health care costs in PsA was $32,791. CONCLUSIONS: In this study, annual managed care per patient direct PsA healthcare costs were $16,369. This new economic burden of illness estimate may further aid decision makers in assessing the cost-effectiveness and budgetary impact of PsA therapies, including biologics. This estimate, however, should be considered in the context of incremental improvements in clinical outcomes associated with biologic treatments compared with older PsA therapies.
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